Goto

Collaborating Authors

Extending Human Lifespans: Using Artificial Intelligence To Find Anti-Aging Chemical Compounds

#artificialintelligence

The University of Surrey has built an artificial intelligence (AI) model that identifies chemical compounds that promote healthy aging -- paving the way towards pharmaceutical innovations that extend a person's lifespan. In a paper published by Nature Communication's Scientific Reports, a team of chemists from Surrey built a machine learning model based on the information from the DrugAge database to predict whether a compound can extend the life of Caenorhabditis elegans -- a translucent worm that shares a similar metabolism to humans. The worm's shorter lifespan gave the researchers the opportunity to see the impact of the chemical compounds. "Ageing is increasingly being recognized as a set of diseases in modern medicine, and we can apply the tools of the digital world, such as AI, to help slow down or protect against aging and age-related diseases. Our study demonstrates the revolutionary ability of AI to aid the identification of compounds with anti-aging properties."


Surrey builds AI to find anti-ageing chemical compounds

#artificialintelligence

In a paper published by Nature Communication's Scientific Reports, a team of chemists from Surrey built a machine learning model based on the information from the DrugAge database to predict whether a compound can extend the life of Caenorhabditis elegans – a translucent worm that shares a similar metabolism to humans. The worm's shorter lifespan gave the researchers the opportunity to see the impact of the chemical compounds. "Ageing is increasingly being recognised as a set of diseases in modern medicine, and we can apply the tools of the digital world, such as AI, to help slow down or protect against ageing and age-related diseases. Our study demonstrates the revolutionary ability of AI to aid the identification of compounds with anti-ageing properties." "This research shows the power and potential of AI, which is a speciality of the University of Surrey, to drive significant benefits in human health."



Deep learning transforms the drug discovery process in collaboration between Insilico Medicine and Life Extension

#artificialintelligence

In March 2016 Insilico Medicine initiated a research collaboration with Life Extension to apply advanced bioinformatic methods and deep learning algorithms to screen for naturally occurring compounds that may slow down or even reverse the cellular and molecular mechanisms of aging. Today Life Extension (LE) launched a new line of nutraceuticals called GEROPROTECTTM, and the first product in the series called Ageless CellTM combines some of the natural compounds that were shortlisted by Insilico Medicine's algorithms and are generally recognized as safe (GRAS). "Life Extension's mission is to extend the healthy human lifespan; and as such, we are focused on identifying natural products with critical health and wellness properties," said Andrew G. Swick, PhD, senior vice president of scientific affairs, discovery research and product development for Life Extension. "Our collaboration with Insilico Medicine fostered a novel approach to formulating anti-aging supplements utilizing artificial intelligence and sophisticated biologically-inspired algorithms and resulted in the very first AI formulated supplement," Swick said. The global nutraceuticals market was valued at US$165.62 billion in 2014 by Transparency Market Research and is expected to reach US$278.96 billion by 2021.


A Search for Anti-Aging Secrets Starts With the Blood of 600 Estonians

WIRED

Silicon Valley runs on two things: obscene amounts of cash and the tales people tell about who they are. Which is perhaps why the Bay Area has rapidly become ground zero for people pursuing one of the oldest mythologies in human history--the legend of everlasting life. Call it healthspan extension, call it geroprotection: Silicon Valley wants to find a way to keep humans healthier for like, way longer. What was once a fringe science is rapidly becoming one of the Valley's hottest investments, thanks to high profile endeavors like Alphabet's $1.5 billion bet on Calico and Bezos and Thiel-backed Unity Biotechnology. Most of the excitement around these ventures rests in the drugs they're developing--pills to prevent damaged proteins and treatments to flush out toxic cells.